Organovo Holdings Inc (NYSEMKT:ONVO), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced that its wholly-owned subsidiary, Samsara Sciences, Inc. (“Samsara”), has launched commercial operations. Samsara’s core mission is the provision of high-quality primary human liver cells for a wide variety of in vivo and in vitro research applications.

Samsara is expected to serve as a key source of primary human liver cells for Organovo’s needs in the preclinical safety and therapeutic tissues markets, allowing the Company to optimize its supply chain and operating expenses related to cell sourcing and procurement. Organovo sought to establish Samsara as a cell provider in part to support the needs of high-quality cell supply for use in the research and development of bioprinted liver tissue as a potential therapeutic product. Samsara will also provide such cells to life science customers through typical commercial channels.

Samsara will offer a comprehensive selection of human hepatic stellate cells – a key cell type in the liver that plays a major role in the development of prevalent diseases such as fatty liver disease and fibrosis. In addition to receiving detailed culture and cryopreservation protocols with each lot of cells, Samsara’s customers will have access to a full portfolio of companion services including the provision of tissue sections, nucleic acids and gene expression data. Human hepatocytes will also be made available through established distribution channels. To achieve its goals, Samsara works closely with key collaborator and liver cell biology expert, Dr. Tatiana Kisseleva and her laboratory at the University of California, San Diego School of Medicine.

“The Samsara team shares a passion for cells and is dedicated to providing the high-quality, well-characterized cellular reagents that are required to support the future of biological research and tissue products,” said Dr. Sharon Presnell, President, Samsara Sciences and Chief Technology Officer and Executive Vice President of Research & Development, Organovo. “Our ultimate vision is to supply a comprehensive portfolio of tissue-specific cells that are tailored for use in the production of the multi-cellular 3D tissues that are poised to change the landscape of drug discovery and regenerative medicine.”

“Cell supply and quality are critical to meeting Organovo’s goal to change the shape of medical research and practice, including our desire to create a bioprinted liver patch for transplant,” said Keith Murphy, CEO, Organovo. “I’m grateful to the team at Samsara and its key collaborators and scientific advisors for enabling us to develop this high-quality cell source, and to offer it to other researchers through Samsara’s commercial efforts.” (Original Source)

Shares of Organovo Holdings closed yesterday at $2.01. ONVO has a 1-year high of $6.85 and a 1-year low of $1.90. The stock’s 50-day moving average is $2.78 and its 200-day moving average is $3.06.

On the ratings front, Jefferies Co. analyst Brandon Couillard reiterated a Buy rating on ONVO, with a price target of $4, in a report issued on October 12. The current price target implies an upside of 99.0% from current levels. According to, Couillard has a total average return of 10.0%, a 70.1% success rate, and is ranked #243 out of 3609 analysts.

Organovo Holdings Inc is a development-stage company. It is engaged in developing and commercializing functional human tissues.